NCT06929533 Pharmacogenomics-Supported Psychotropic Prescribing Trial
| NCT ID | NCT06929533 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Manitoba |
| Condition | Mental Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-07-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated * The treating clinician thinks PGx testing can benefit and refers the patient to the study Exclusion Criteria: * Unwillingness to donate saliva samples for genetic analysis * History of liver or bone marrow (hematopoietic cell) transplantation * PGx testing results are already available * No personal health identification number (PHIN) is available
Contact & Investigator
Abdullah Al Maruf, PhD, M.Pharm., B.Pharm
PRINCIPAL INVESTIGATOR
University of Manitoba
Frequently Asked Questions
Who can join the NCT06929533 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Mental Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06929533 currently recruiting?
Yes, NCT06929533 is actively recruiting participants. Contact the research team at abdullah.maruf@umanitoba.ca for enrollment information.
Where is the NCT06929533 trial being conducted?
This trial is being conducted at Winnipeg, Canada, Winnipeg, Canada.
Who is sponsoring the NCT06929533 clinical trial?
NCT06929533 is sponsored by University of Manitoba. The principal investigator is Abdullah Al Maruf, PhD, M.Pharm., B.Pharm at University of Manitoba. The trial plans to enroll 200 participants.